Regulation of fibrin-mediated tumor cell adhesion to the endothelium using anti-thrombin aptamer

Erin R. Gaddes, Deborah Lee, Gregory Gydush, Yong Wang, Cheng Dong

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Molecular intervention during transient stages of various metastatic pathways may lead to development of promising therapeutic technologies. One of such involves soluble fibrin (sFn) that has been implicated as a cross-linker between circulating blood or tumor cells and endothelial cell receptors, promoting cell arrest on the endothelium during circulation. sFn generation is a result of thrombin-mediated fibrinogen (Fg) cleavage due to either vascular injuries or a tumor microenvironment. For cancer therapy, thrombin-mediated conversions of Fg to sFn thus serve as potential intervention points to decrease circulating tumor cell adhesion to the endothelium and subsequent metastatic events. The purpose of this work was to investigate the function of an anti-thrombin oligonucleotide aptamer in reducing tumor cell arrest. Both molecular and cellular interactions were examined to demonstrate the binding and inhibitory effects of anti-thrombin aptamer. The results show that the aptamer is capable of inhibiting thrombin-mediated Fg conversion, thereby reducing sFn-mediated tumor cell adhesion in a concentration-dependent manner. Notably, the aptamer is able to bind thrombin under dynamic flow conditions and reduce tumor cell adhesive events at various physiological shear rates. This study further indicates that oligonucleotide aptamers hold great promise as therapeutic regulators of tumor cell adhesion, and consequently, metastatic activity.

Original languageEnglish (US)
Pages (from-to)417-426
Number of pages10
JournalExperimental Cell Research
Volume339
Issue number2
DOIs
StatePublished - Dec 1 2015

All Science Journal Classification (ASJC) codes

  • Cell Biology

Fingerprint Dive into the research topics of 'Regulation of fibrin-mediated tumor cell adhesion to the endothelium using anti-thrombin aptamer'. Together they form a unique fingerprint.

Cite this